Vaccines being developed by drug makers Johnson & Johnson and Novavax show promising results, potentially adding to the U.S. arsenal of weapons against COVID-19.
But both show reduced efficacy against the highly contagious variant first identified in South Africa.
Today on Wellness Wednesday on All Sides with Ann Fisher, we talk about the new vaccines and concerns of an evolving viral threat.
Guests:
- Ana Maldonado-Contreras, Ph.D., assistant professor of microbiology and physiological systems, University of Massachusetts Medical School
- Carl Zimmer, science columnist, The New York Times
- George Kyriazis, assistant professor of biological chemistry and pharmacology, Ohio State University
If you have a disability and experience difficulty accessing this content request an alternative format.
